
    
      Subjects with a diagnosis of progressive keratoconus will be evaluated for suitability as a
      candidate for Corneal Crosslinking (CXL). Subjects that as candidates for CXL will be asked
      to participate in this study and will undergo the required screening procedures to determine
      study eligibility. Informed consent will be obtained from each subject before performance of
      any required any required study procedures that are not part of the investigator's routine
      examination. All Subjects will be evaluated at screening/baseline, Day 0 (treatment day),
      then 1 day, 1 week, and 1, 3, 6, 12 months after treatment. Pentacam measurements and
      measurements of best spectacle-corrected visual acuity will be obtained and baseline and at
      appropriate times after the epithelium-on CXL procedure. Safety monitoring throughout the
      study will include observations at appropriate times for adverse events, clinically
      significant findings on ophthalmic examination, and slit-lamp examination.

      The primary efficacy parameter is the change from baseline over time in maximum keratometry
      (K-Max). Addition analyses for efficacy will include uncorrected visual acuity (UCVA) and
      best corrected visual acuity (BCVA).
    
  